PE20211697A1 - Anticuerpos monoclonales especificos para el antigeno pb2 del virus de la influenza humana (flu), secuencias nucleotidicas; metodo y kit de diagnostico de infeccion producida por flu - Google Patents
Anticuerpos monoclonales especificos para el antigeno pb2 del virus de la influenza humana (flu), secuencias nucleotidicas; metodo y kit de diagnostico de infeccion producida por fluInfo
- Publication number
- PE20211697A1 PE20211697A1 PE2021001088A PE2021001088A PE20211697A1 PE 20211697 A1 PE20211697 A1 PE 20211697A1 PE 2021001088 A PE2021001088 A PE 2021001088A PE 2021001088 A PE2021001088 A PE 2021001088A PE 20211697 A1 PE20211697 A1 PE 20211697A1
- Authority
- PE
- Peru
- Prior art keywords
- flu
- monoclonal antibodies
- influenza virus
- diagnostic kit
- antigen
- Prior art date
Links
- 206010022000 influenza Diseases 0.000 title abstract 6
- 238000009007 Diagnostic Kit Methods 0.000 title abstract 2
- 238000002405 diagnostic procedure Methods 0.000 title abstract 2
- 208000015181 infectious disease Diseases 0.000 title abstract 2
- 241000712461 unidentified influenza virus Species 0.000 title abstract 2
- 108091028043 Nucleic acid sequence Proteins 0.000 title 1
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 239000012634 fragment Substances 0.000 abstract 2
- 239000012472 biological sample Substances 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1018—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/11—Orthomyxoviridae, e.g. influenza virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/10—Detection of antigens from microorganism in sample from host
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
La invencion presenta la generacion de anticuerpos monoclonales, o fragmentos de los mismos, que reconocen la proteina PB2 del virus de la influenza humana (Flu), donde dichos anticuerpos monoclonales o fragmentos de estos, comprenden una region variable de la cadena pesada y una region variable de la cadena liviana. Ademas, se proporciona un metodo de diagnostico para detectar infecciones por Flu en muestras biologicas de secreciones nasofaringeas, utilizando los anticuerpos monoclonales en formato de kit de diagnostico.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CL2018003871A CL2018003871A1 (es) | 2018-12-28 | 2018-12-28 | Anticuerpos monoclonales específicos para el antígeno pb2 del virus de la influenza humana (flu), secuencias nucleotídicas; método y kit de diagnóstico de infección producida por flu |
PCT/CL2019/050155 WO2020132772A1 (es) | 2018-12-28 | 2019-12-27 | Anticuerpos monoclonales específicos para el antígeno pb2 del virus de la influenza humana (flu), secuencias nucleotídicas; método y kit de diagnóstico de infección producida por flu |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20211697A1 true PE20211697A1 (es) | 2021-09-01 |
Family
ID=71125619
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2021001088A PE20211697A1 (es) | 2018-12-28 | 2019-12-27 | Anticuerpos monoclonales especificos para el antigeno pb2 del virus de la influenza humana (flu), secuencias nucleotidicas; metodo y kit de diagnostico de infeccion producida por flu |
Country Status (14)
Country | Link |
---|---|
US (1) | US20220119503A1 (es) |
EP (1) | EP3904380A4 (es) |
KR (1) | KR20210110662A (es) |
CN (1) | CN113490684A (es) |
AR (1) | AR117546A1 (es) |
BR (1) | BR112021012792A2 (es) |
CA (1) | CA3125206A1 (es) |
CL (1) | CL2018003871A1 (es) |
CO (1) | CO2021008774A2 (es) |
MX (1) | MX2021007871A (es) |
PE (1) | PE20211697A1 (es) |
UY (1) | UY38533A (es) |
WO (1) | WO2020132772A1 (es) |
ZA (1) | ZA202104989B (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115057925B (zh) * | 2022-06-22 | 2024-03-26 | 中国检验检疫科学研究院 | 一种抗赤羽病病毒单克隆抗体及其应用 |
CN115925891A (zh) * | 2022-07-05 | 2023-04-07 | 东莞市朋志生物科技有限公司 | 抗乙型流感病毒抗体、检测乙型流感病毒的试剂和试剂盒 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080292658A1 (en) * | 2004-11-11 | 2008-11-27 | Emmie De Wit | Defective Influenza Virus Particles |
EP2197901B1 (en) * | 2007-10-09 | 2013-12-11 | European Molecular Biology Laboratory (Embl) | Soluble fragments of influenza virus pb2 protein capable of binding rna-cap |
JP2013540701A (ja) * | 2010-08-12 | 2013-11-07 | セラクローン サイエンシーズ, インコーポレイテッド | 抗赤血球凝集素抗体組成物およびその使用方法 |
US20130289246A1 (en) | 2010-09-30 | 2013-10-31 | Vanderbilt University | Influenza virus antibodies and immunogens and uses therefor |
US9650434B2 (en) | 2013-04-02 | 2017-05-16 | Xiamen University | Broad-spectrum monoclonal antibody recognizing HA1 domain of hemagglutinin of influenza virus |
JP6614523B2 (ja) | 2014-03-28 | 2019-12-04 | 地方独立行政法人神奈川県立産業技術総合研究所 | インフルエンザウイルスのrna依存性rnaポリメラーゼのpb2サブユニットに対するモノクローナル抗体 |
WO2016047592A1 (ja) * | 2014-09-22 | 2016-03-31 | 国立研究開発法人科学技術振興機構 | 抗インフルエンザウイルス剤、及び抗インフルエンザウイルス剤のスクリーニング方法 |
-
2018
- 2018-12-28 CL CL2018003871A patent/CL2018003871A1/es unknown
-
2019
- 2019-12-27 WO PCT/CL2019/050155 patent/WO2020132772A1/es unknown
- 2019-12-27 US US17/418,608 patent/US20220119503A1/en active Pending
- 2019-12-27 UY UY0001038533A patent/UY38533A/es unknown
- 2019-12-27 AR ARP190103906A patent/AR117546A1/es unknown
- 2019-12-27 CA CA3125206A patent/CA3125206A1/en active Pending
- 2019-12-27 BR BR112021012792A patent/BR112021012792A2/pt unknown
- 2019-12-27 KR KR1020217024089A patent/KR20210110662A/ko unknown
- 2019-12-27 PE PE2021001088A patent/PE20211697A1/es unknown
- 2019-12-27 EP EP19905189.7A patent/EP3904380A4/en active Pending
- 2019-12-27 CN CN201980093160.6A patent/CN113490684A/zh active Pending
- 2019-12-27 MX MX2021007871A patent/MX2021007871A/es unknown
-
2021
- 2021-07-01 CO CONC2021/0008774A patent/CO2021008774A2/es unknown
- 2021-07-15 ZA ZA2021/04989A patent/ZA202104989B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA3125206A1 (en) | 2020-07-02 |
ZA202104989B (en) | 2023-01-25 |
KR20210110662A (ko) | 2021-09-08 |
CO2021008774A2 (es) | 2021-07-19 |
AR117546A1 (es) | 2021-08-11 |
CN113490684A (zh) | 2021-10-08 |
US20220119503A1 (en) | 2022-04-21 |
WO2020132772A1 (es) | 2020-07-02 |
CL2018003871A1 (es) | 2021-01-15 |
MX2021007871A (es) | 2021-12-10 |
UY38533A (es) | 2020-07-31 |
EP3904380A1 (en) | 2021-11-03 |
BR112021012792A2 (pt) | 2021-11-16 |
EP3904380A4 (en) | 2022-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2019000067A1 (es) | Anticuerpos nuevos que se unen específicamente a los epítopos del virus del zika y usos de los mismos. | |
CO2021008774A2 (es) | Anticuerpos monoclonales específicos para el antígeno pb2 del virus de la influenza humana (flu), secuencias nucleotídicas; método y kit de diagnóstico de infección producida por flu | |
PE20170665A1 (es) | Anticuerpos anti-tau humanizados | |
AR095432A1 (es) | Proteínas de unión a antígeno | |
ECSP14020644A (es) | Anticuerpos dirigidos contra metaloproteinasas de matriz 9 | |
CU24568B1 (es) | Anticuerpo inhibidor de masp-3 | |
CR20130132A (es) | Anticuerpos contra metalproteasa-9 de matriz | |
CO6220862A2 (es) | Anticuerpos neutralizantes de citomegalovirus humano y su uso | |
PE20081686A1 (es) | Proteinas de fusion que comprenden un antigeno prame (dage) | |
PE20220004A1 (es) | Anticuerpos monoclonales especificos para el antigeno p del virus respiratorio sincicial humano (vrsh), producidos y secretados por hibridomas celulares, utiles para la deteccion y el diagnostico de la infeccion causada por vrsh | |
PE20220708A1 (es) | Anticuerpos anti-cd73 | |
PE20141683A1 (es) | Anticuerpos monoclonales especificos para el antigeno m2-1 del virus respiratorio sincicial (vrs) | |
CL2020003391A1 (es) | Proteína de unión al antígeno anti-steap1 | |
PE20230075A1 (es) | Anticuerpos anti-flt3 y composiciones | |
CL2023001462A1 (es) | Anticuerpos ampliamente neutralizantes contra la neuraminidasa de influenza | |
PE20181498A1 (es) | Anticuerpos monoclonales especificos para el antigeno piii de adenovirus humano (adv), producidos y secretados por hibridomas celulares, utiles para la deteccion y el diagnostico de la infeccion causada por adv | |
AR087654A1 (es) | METODO DIAGNOSTICO DE ANIMALES VACUNADOS CON PESTIVIRUS QUIMERICO EN EL CUAL LA PROTEINA Eʳⁿˢ DEL VIRUS DE LA DIARREA VIRAL BOVINA (BVDV) ES REMPLAZADA POR PROTEINA Eʳⁿˢ DE PESTIVIRUS DE ANTILOPE AMERICANO | |
CO2021008770A2 (es) | Anticuerpos monoclonales específicos para la proteína quimérica l del virus de la parainfluenza humana (piv), secuencias nucleotídicas; método y kit de diagnóstico de infección producida por piv | |
UY37752A (es) | Proteínas de unión al antígeno anti-jagged1 | |
EA201991843A1 (ru) | Способ иммунологического определения специфических антител к антигенам вирусов семейства поксвирусов | |
PE20171734A1 (es) | Anticuerpos monoclonales especificos del antigeno m del virus metapneumovirus humano (hmpv) y su uso en un metodo de diagnostico | |
AR041230A1 (es) | Anticuerpo monoclonal especifico para un epitope de glicoproteina codificada por el virus inactivado de la inmunodeficiencia felina | |
EA202190351A1 (ru) | Композиция, входящая в состав вакцины против гриппа | |
AR116241A1 (es) | Método para predecir la respuesta terapéutica y/o la progresión de la enfermedad en un sujeto que sufre chagas | |
EA201991851A1 (ru) | Антитела против sirp-альфа |